← Back to all substances
A

sitagliptin

224ms
Level 1

✓ What this shows

  • • Reported adverse events from FDA FAERS
  • • Descriptive statistics from a locked corpus
  • • Data verified with cryptographic hashes

✗ What this is NOT

  • • Not medical advice or recommendations
  • • Not proof of causality
  • • Not a complete safety profile

About this substance

Class: Dipeptidyl Peptidase 4 Inhibitor [EPC]

1 INDICATIONS AND USAGE ZITUVIMET is a combination of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Z...

Known as: ZITUVIMET
Route: ORAL
Source: OpenFDA Drug Labels · Reference only · Not medical advice
500
Events in Corpus
v20260131-01
15,775
Total in FDA
93%
Serious Reports
70
Fatal Outcomes

Seriousness

Serious
466
Non-Serious
34

Sex Distribution

Male
269
Female
198
Unknown
33

Age Distribution

0-17
4
18-40
14
41-64
173
65-84
225
85+
17
Unknown
67

Outcomes

Recovered/Resolved
550
Recovering/Resolving
157
Not Recovered/Not Resolved
191
Recovered with Sequelae
15
Fatal
70
Unknown
564

Top Reported Reactions (click to view reports)

Verification Data

Corpus Version: v20260131-01
Root Hash: ec5727564d1ed19be5b08b26d3866f446b12d3d388f5a8cd713332c6d97ad264
Stats Hash: N/A
EVE Decision ID: EVE-MED-20260402-d2964d
ℹThis output reports adverse events from FDA FAERS. It does not constitute medical advice.

Molecular Structure (reference)

Structural visualization for identification only.

This visualization shows the molecular structure for identification purposes only. It does not represent pharmacological effect, safety, or clinical relevance.

Loading structure...